Donanemab

Donanemab is an experimental medication being studied for the treatment of Alzheimer's disease. It belongs to a class called monoclonal antibodies, which are designed to target and help remove amyloid plaques—abnormal protein clumps in the brain associated with Alzheimer's. By addressing these plaques, donanemab aims to slow down cognitive decline in patients with early stages of the disease. Clinical trials are ongoing to assess its effectiveness and safety. If successful, it could offer new hope for individuals and families affected by Alzheimer's.